Fermenta Biotech

Fermenta Biotech Payables Turnover

The Payables Turnover Ratio of Fermenta Biotech (506414.BO) as of Nov 16, 2026 is 2.46. In the previous year, Payables Turnover Ratio was 2.50 — a change of -1.84% (lower).

Payables Turnover

2.46

YoY

-1.84%

Last updated:

Payables Turnover Ratio of Fermenta Biotech is 2025 2.46 . Payables Turnover Ratio of Fermenta Biotech was 2024 2.50 . It decreases by -1.84% lower compared to the previous year.

The Fermenta Biotech Payables Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Payables Turnover
Date
Payables Turnover
Jan 1, 2018
2.49 INR
Jan 1, 2019
2.73 INR
Jan 1, 2020
1.80 INR
Jan 1, 2021
2.53 INR
Jan 1, 2022
2.87 INR
Jan 1, 2023
3.97 INR
Jan 1, 2024
2.50 INR
Jan 1, 2025
2.46 INR
The Fermenta Biotech Payables Turnover history
YEARPayables TurnoverYoY
2.46-1.84%
2.50-36.95%
3.97+38.31%
2.87+13.30%
2.53+40.72%
1.80-34.16%
2.73+9.54%
2.49-3.11%
2.57-23.82%
3.38-15.35%
3.99-0.65%
4.02—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fermenta Biotech Stock analysis

What does Fermenta Biotech do? Fermenta Biotech Ltd manufactures and supplies Vitamin D3, operating through its Chemicals/Bulk Drug segment that produces bulk drugs and enzymes for pharmaceuticals, dietary supplements, food fortification, animal feed, veterinary, and rodenticide industries. The Property segment generates revenue by renting and selling properties. The company's proprietary enzyme portfolio supports biopharmaceutical product development, while its nutritional ingredients include fish oil-derived cholesterol for aquaculture, natural astaxanthin, and vitamin AD2 premix, all sold to customers in the specified sectors. The Chemicals/Bulk Drug segment serves pharmaceutical, dietary supplement, food and beverage, animal feed, veterinary, and rodenticide markets with bulk drugs and enzymes. The Property segment focuses on real estate transactions, providing rental and sales services for its properties. Fermenta Biotech's product portfolio targets industries requiring specialized biopharmaceutical technologies and nutritional supplements, with key offerings like Vitamin D3, fish oil cholesterol, astaxanthin, and vitamin AD2 premix directly sold to these sectors. Fermenta Biotech Ltd's revenue streams come from the sale of Vitamin D3 and other bulk drugs through its Chemicals/Bulk Drug segment, while the Property segment contributes through property rentals and sales. The company's nutritional ingredients, such as fish oil-derived cholesterol, natural astaxanthin, and vitamin AD2 premix, are sold to industries including pharmaceuticals, dietary supplements, food fortification, animal feed, and veterinary sectors, with no additional brand or customer details provided beyond the business description. Fermenta Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fermenta Biotech stock

Payables Turnover Ratio of Fermenta Biotech is 2.46 in 2025.

Payables Turnover Ratio of Fermenta Biotech changed from 2.50 to 2.46, representing a -1.84% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Payables Turnover Ratio Fermenta Biotech since 2006 – with annual values, charts, and detailed analysis.

Payables turnover measures how quickly a company pays its suppliers. Lower turnover may indicate better payment terms or cash flow management.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Payables Turnover Ratio's Fermenta Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate Payables Turnover Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Payables Turnover Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Fermenta Biotech

All Key Metrics — Fermenta Biotech